



2024

Taipei International Breast Cancer Symposium

台北國際乳癌研討會

Speech Abstract

Topic:

Novel Strategies to Overcome Resistance to ET in HR+ aBC: From Biological Perspectives to Clinical Advances

Abstract

Recent advancements in treating HR+ advanced breast cancer have highlighted the crucial role of the PI3K/AKT/mTOR pathway in endocrine resistance, significantly impacting patient prognosis. The development of inhibitors targeting key nodes within this pathway is continuously evolving. In this context, Dr. Cortes will deep dive into the biological rationale for inhibiting AKT in ER-positive mBC and provide a comprehensive analysis of the latest clinical trial evidence related to HR+ aBC. By examining how novel targeted therapies are reshaping current treatment paradigms, Dr. Cortes will elucidate the specific influence of the PI3K/AKT/mTOR pathway on clinical outcomes and treatment efficacy. This discussion will offer valuable insights into optimizing therapeutic strategies for HR+ aBC patients.